Skip to main content
. 2019 Jun 20;22(6):329–335. [Article in Chinese] doi: 10.3779/j.issn.1009-3419.2019.06.01

3.

3

肺炎型肺癌患者的总生存期。A：化疗组患者对比无化疗组患者的Kaplan-Meier生存曲线；B：EGFR突变或ALK重排的患者对比无EGFR突变或ALK重排患者的Kaplan-Meier生存曲线；C：无EGFR或ALK重排的患者，化疗组对比无化疗组的Kaplan-Meier生存曲线。

Overall survival in patients with pneumonic-type lung carcinoma. A: Kaplan-Meier estimates in patients with chemotherapy versus non-chemotherapy. B: Kaplan-Meier estimates in patients with EGFR mutation or ALK rearrangement versus patients without EGFR mutation or ALK rearrangement. C: Kaplan-Meier estimates in patients without EGFR mutation or ALK arrangement with chemotherapy versus non-chemotherapy.